INVO Fertility (NASDAQ:IVF) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of INVO Fertility (NASDAQ:IVF) to a hold rating in a research note published on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of INVO Fertility in a report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $20.00.

INVO Fertility Stock Performance

Shares of IVF stock opened at $1.03 on Friday. The company has a market capitalization of $2.59 million, a price-to-earnings ratio of -0.03 and a beta of 2.32. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.67 and a current ratio of 0.71. The company has a 50-day simple moving average of $1.20 and a 200 day simple moving average of $2.19. INVO Fertility has a 52 week low of $0.90 and a 52 week high of $84.40.

INVO Fertility (NASDAQ:IVF) last announced its quarterly earnings results on Friday, August 14th. The company reported $0.35 EPS for the quarter. The business had revenue of $2.18 million for the quarter. INVO Fertility had a negative net margin of 116.29% and a negative return on equity of 85.54%.

Institutional Investors Weigh In On INVO Fertility

An institutional investor recently bought a new stake in INVO Fertility stock. Armistice Capital LLC purchased a new stake in INVO Fertility, Inc (NASDAQ:IVF) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 207,644 shares of the company’s stock, valued at approximately $156,000. Armistice Capital LLC owned approximately 8.69% of INVO Fertility as of its most recent filing with the Securities & Exchange Commission. 12.02% of the stock is currently owned by institutional investors and hedge funds.

INVO Fertility Company Profile

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.